Aida Chan
Mary Gates Research Scholar
Autumn 2025
Project
RiboRDT: Leveraging Ribosomal Proteins as Novel Biomarkers for Rapid Diagnostic Tests
Malaria remains one of the world’s most persistent public health challenges, disproportionately affecting low-income regions of Sub-Saharan Africa where access to reliable diagnostic tests and timely, effective treatment is limited. Rapid Diagnostic Tests (RDTs) are essential for point-of-care malaria detection; however, the growing prevalence of deletions in the Plasmodium falciparum hrp2 gene has significantly compromised the sensitivity of HRP2-based RDTs, which constitute the majority of RDTs currently in use. Failures in these tests result in false-negative diagnoses even in patients with active parasitemia, thus delaying treatment, enabling continued transmission, and undermining malaria surveillance and control efforts. To address this diagnostic gap, we present a study that aims to evaluate the potential of ribosomal proteins (RPs) as alternative diagnostic biomarkers for P. falciparum infection. We identified four promising RP candidates — all of which are highly expressed, essential for parasite survival, and unlikely to be lost through gene deletions, rendering them strong targets for specific and durable detection. Plasmids encoding these targets will be delivered to mice via gene gun-mediated immunization to generate RP-specific antibodies. The resulting purified mouse IgG will be assessed using dot blot assays to determine whether these antibodies can reliably discriminate P. falciparum-infected red blood cells from uninfected controls. Ultimately, this approach seeks to establish the feasibility of RP-based detection as a foundation for next-generation malaria RDTs, addressing a critical vulnerability of current HRP2-dependent diagnostics and offering innovative alternatives in the face of HRP2 deletions.